Journal: Vaccine
Lead Author: Lazaros et al.
Original date of publication: 07/01/2021
Link: https://pubmed.ncbi.nlm.nih.gov/34312010/
Keywords: covid vaccinationCOVID-19; Myocarditis; mRNA vaccines; mRNA-LNP stability; adverse events
Full Author List: George Lazaros, Allan L Klein, Sophia Hatziantoniou, Costas Tsioufis, Athanasios Tsakris, Cleo Anastassopoulou
Lead Author: Lazaros et al.
Original date of publication: 07/01/2021
Link: https://pubmed.ncbi.nlm.nih.gov/34312010/
Summary Context
An attempt to describe mehcnais behind myocarditis increase after mRNA inection, mostly blaming some batches that were potentially contaminated
Comments
This article is copyrighted by Health Freedom Defense Fund, Inc.
Visit our Re-post guidelines
Visit our Re-post guidelines
This paper is an attempt to describe the mechanisms behind myocarditis after mRNA vaccination, and uniquely, the authors blame variation in this product specifically.
Abstract or Results, Key Passages
“Accordingly, some early commercial batches of the Pfizer-BioNTech’s vaccine contained lower than expected levels of intact mRNA as shown by leaked EMA documents [6]. In an email dated November 23, an EMA official outlined a raft of issues on “truncated and modified mRNA species present in the finished product,” with unknown consequences on vaccine safety and efficacy.”
Keywords: covid vaccinationCOVID-19; Myocarditis; mRNA vaccines; mRNA-LNP stability; adverse events
Full Author List: George Lazaros, Allan L Klein, Sophia Hatziantoniou, Costas Tsioufis, Athanasios Tsakris, Cleo Anastassopoulou
